The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias)
Foy, Victoria (Christie Hospital)
Raby, Sophie (Christie Hospital)
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia))
Macía-Rivas, Lola (Hospital Universitario Central de Asturias)
Arrazubi, Virginia (Complejo Hospitalario de Navarra)
Cacho Lavin, Diego (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Hernandez San Gil, Raquel (Hospital Universitario de Canarias (La Laguna))
Custodio, Ana (Hospital Universitario La Paz (Madrid))
Cano, Juana María (Hospital General Universitario de Ciudad Real)
Fernández Montes, Ana (Complejo Hospitalario de Ourense)
Mirallas, Oriol (Hospital Universitari Vall d'Hebron)
Macias Declara, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Vidal Tocino, Rosario (Complejo Asistencial Universitario de Salamanca-IBSAL)
Visa, Laura (Hospital Universitario El Mar)
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Pimentel, Paola (Hospital General Universitario Santa Lucía (Cartagena, Múrcia))
Martínez Lago, Nieves (Complejo Hospitalario Universitario de A Coruña)
Saurí Nadal, Tamara (Hospital Clínic i Provincial de Barcelona)
Martín Richard, Marta (Institut Català d'Oncologia)
Mangas, Monserrat (Hospital de Galdakao (Usansolo, Biscaia))
Gil Raga, Mireia (Hospital General Universitario de Valencia)
Calvo, Aitana (Hospital General Universitario Gregorio Marañón)
Reguera, Pablo (Hospital Universitario Ramón y Cajal (Madrid))
Granja, Mónica (Hospital Universitario Clínico San Carlos (Madrid))
Martín Carnicero, Alfonso (Hospital San Pedro de Alcántara)
Hernández Pérez, Carolina (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife))
Cerdà, Paula (Institut d'Investigació Biomèdica Sant Pau)
Gomez Gonzalez, Lucía (Hospital General Universitario de Alicante (Alacant, País Valencià))
Garcia Navalon, Francisco (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Pacheco-Barcia, Vilma (Hospital Universitario de Torrejón)
Gutierrez Abad, David (Hospital Universitario de Fuenlabrada ( Madrid))
Ruiz Martín, Maribel (Hospital Universitario Rio Carrión de Zamora)
Weaver, Jamie (Christie Hospital/University of Manchester)
Mansoor, Wasat (Christie Hospital/University of Manchester)
Gallego, Javier (Hospital General Universitario de Elche)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7. 76 [95% confidence interval (CI), 7. 13-8. 25] and 14. 0 months (95% CI, 13. 0-14. 9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0. 606 (95% CI, 0. 578-0. 636) and 0. 623 (95% CI, 0. 594-0. 655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0. 650 and 0. 683 for PFS and OS, respectively. The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	HER2-positive ; Gastric cancer ; Nomogram ; Oesophageal cancer ; Survival ; Trastuzumab
Published in:	Therapeutic Advances in Medical Oncology, Vol. 15 (1-12 2023) , ISSN 1758-8359

DOI: 10.1177/17588359231157641
PMID: 36895850

16 p, 873.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles